Inicio / Metabolismo Óseo y Mineral (página 3)

Metabolismo Óseo y Mineral

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84

Última actualización 19/11/08Bone. 2008 Oct 17. [Epub ahead of print] Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J. Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac …

Leer más »

Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial

Última actualización 19/11/08J Bone Joint Surg Am. 2008 Nov;90(11):2346-53. Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. BACKGROUND: Although osteoporosis is strongly associated with hip fractures, the initiation of osteoporosis treatment following hip fractures occurs at surprisingly low rates of between 5% and 30%. Currently, most patients receiving …

Leer más »

Effect of alendronate in elderly patients after low trauma hip fracture repair

Última actualización 13/11/08Osteoporos Int. 2008 Oct 28. [Epub ahead of print] Cecilia D, Jódar E, Fernández C, Resines C, Hawkins F. One year of once weekly alendronate, when given shortly after the surgical repair of a hip fracture, produces reductions in bone markers and increases proximal femoral bone density. The …

Leer más »

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

Última actualización 13/10/08J Intern Med. 2008 Oct;264(4):315-32. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and …

Leer más »

Pathogenesis and management of Paget’s disease of bone.

Última actualización 20/08/08Lancet. 2008 Jul 12;372(9633):155-63. Ralston SH, Langston AL, Reid IR. Paget’s disease of bone is a common disease characterised by focal areas of increased bone turnover, affecting one or several bones throughout the skeleton. Paget’s disease is often asymptomatic but can be associated with bone pain and other …

Leer más »

Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling

Última actualización 8/07/08NULL Bone. 2008 Jun 3. [Epub ahead of print] McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Orthopaedic Research and Biotechnology, The Children’s Hospital at Westmead, Westmead Australia; Science Department, University of Technology Sydney, Australia. INTRODUCTION: It has been widely assumed that osteoclasts play …

Leer más »

Use of alendronate and risk of incident atrial fibrillation in women

Última actualización 15/05/08NULL Arch Intern Med. 2008 Apr 28;168(8):826-31 Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. BACKGROUND: A recent publication from the HORIZON (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly) trial in women with postmenopausal osteoporosis reported a higher risk of serious atrial fibrillation …

Leer más »

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment

Última actualización 2/05/08NULL Sebba AI. Clin Ther. 2008 Mar;30(3):443-52. Background: Oral bisphosphonates are routinely prescribed for the treatment of postmenopausal osteoporosis. In clinical trials, oral bisphosphonates have been found to increase bone mineral density (BMD) and decrease fracture risk in the majority of the treated population. However, in both clinical …

Leer más »

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

Última actualización 25/03/08NULL Bone. published online 04 March 2008 Rizzoli R. Abstract A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget’s disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is …

Leer más »